Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9.
Weekly epidemiological update on COVID-. 19–1 June 2023. [cited 2024 May 6]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—1-june-2023
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–42.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107–8.
Ayanian S, Reyes J, Lynn L, Teufel K. The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort. Biomark Med. 2020;14(12):1091–7.
Kumar N, Ahmad S, Mahto M, Kumar A, Singh PK. Prognostic value of elevated cardiac and inflammatory biomarkers in patients with severe COVID-19: a single-center, retrospective study. Emerg Crit Care Med. 2022;2(3):122–7.
Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
Lampart M, Zellweger N, Bassetti S, Tschudin-Sutter S, Rentsch KM, Siegemund M, et al. Clinical utility of inflammatory biomarkers in COVID-19 in direct comparison to other respiratory infections-A prospective cohort study. PLoS ONE. 2022;17(5):e0269005.
Miftode RS, Costache II, Constantinescu D, Mitu O, Timpau AS, Hancianu M, et al. Syndecan-1: from a promising novel cardiac biomarker to a surrogate early predictor of kidney and liver injury in patients with acute heart failure. Life (Basel). 2023;13(4):898.
Wernly B, Fuernau G, Masyuk M, Muessig JM, Pfeiler S, Bruno RR, et al. Syndecan-1 predicts outcome in patients with ST-segment elevation infarction independent from infarct-related myocardial injury. Sci Rep. 2019;9(1):18367.
Suzuki K, Okada H, Sumi K, Tomita H, Kobayashi R, Ishihara T, et al. Serum syndecan-1 reflects organ dysfunction in critically ill patients. Sci Rep. 2021;11(1):8864.
Tanino Y. Roles of extracellular matrix in lung diseases. Fukushima J Med Sci. 2024;70(1):1–9.
Wei S, Gonzalez Rodriguez E, Chang R, Holcomb JB, Kao LS, Wade CE, et al. Elevated syndecan-1 after trauma and risk of sepsis: a secondary analysis of patients from the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial. J Am Coll Surg. 2018;227(6):587–95.
Bertrand J, Bollmann M. Soluble syndecans: biomarkers for diseases and therapeutic options. Br J Pharmacol. 2019;176(1):67–81.
Sallisalmi M, Tenhunen J, Yang R, Oksala N, Pettilä V. Vascular adhesion protein-1 and syndecan-1 in septic shock. Acta Anaesthesiol Scand. 2012;56(3):316–22.
Johansson PI, Haase N, Perner A, Ostrowski SR. Association between sympathoadrenal activation, fibrinolysis, and endothelial damage in septic patients: a prospective study. J Crit Care. 2014;29(3):327–33.
Anand D, Ray S, Srivastava LM, Bhargava S. Evolution of serum hyaluronan and syndecan levels in prognosis of sepsis patients. Clin Biochem. 2016;49(10–11):768–76.
Puskarich MA, Cornelius DC, Tharp J, Nandi U, Jones AE. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. J Crit Care. 2016;36:125–9.
Ostrowski SR, Gaïni S, Pedersen C, Johansson PI. Sympathoadrenal activation and endothelial damage in patients with varying degrees of acute infectious disease: an observational study. J Crit Care. 2015;30(1):90–6.
Idogawa M, Tange S, Nakase H, Tokino T. Interactive web-based graphs of coronavirus disease 2019 cases and deaths per population by country. Clin Infect Dis. 2020;71(15):902–3.
001248424.pdf. [cited 2024 May 7]. https://www.mhlw.go.jp/content/001248424.pdf
Hatanaka K, Ito T, Madokoro Y, Kamikokuryo C, Niiyama S, Yamada S, et al. Circulating syndecan-1 as a predictor of persistent thrombocytopenia and lethal outcome: a population study of patients with suspected sepsis requiring intensive care. Front Cardiovasc Med. 2021;8:730553.
Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York city during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis. 2021;21(2):203–12.
Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O’Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9(6):350–9.
Karampoor S, Zahednasab H, Farahmand M, Mirzaei R, Zamani F, Tabibzadeh A, et al. A possible pathogenic role of syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19). Int Immunopharmacol. 2021;97:107684.
Zhang D, Li L, Chen Y, Ma J, Yang Y, Aodeng S, et al. Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19. Mol Med. 2021;27(1):151.
Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission Syndecan-1 level, a marker of endothelial glycocalyx degradation, is Associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254(2):194.
Yamaoka-Tojo M. Vascular endothelial glycocalyx damage in COVID-19. Int J Mol Sci. 2020;21(24):9712.
Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340(2):115–26.
Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120(13):1266–86.
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020;14(4):535–45.
Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–58.
Add Comment